The state of Pennsylvania currently has 17 active clinical trials seeking participants for Pulmonary Fibrosis research studies. These trials are conducted in various cities, including Philadelphia, Pittsburgh, Hershey and Allentown.
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Recruiting
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the th... Read More
Gender:
ALL
Ages:
30 years and above
Trial Updated:
12/18/2024
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
The purposes of this study are: * to determine if there are specific genetic traits that might explain why patients have developed pulmonary fibrosis; * to determine if specific genetic traits account for differing patterns of inflammation and scar tissue that has formed in the patient's lungs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2024
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Pulmonary Fibrosis
Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
The purpose of the study is to identify genetic and biologic markers that may predict the loss of lung function due to idiopathic pulmonary fibrosis. The studies will compare genetic and biologic markers of samples to changes in symptoms. The ultimate goal is to predict if or when patients are likely to experience a rapid decline in lung function due to disease progression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2024
Locations: Michelle F MacPherson, Pittsburgh, Pennsylvania
Conditions: Idiopathic Pulmonary Fibrosis
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
Recruiting
The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary fibrosis.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
10/15/2024
Locations: Temple University, Philadelphia, Pennsylvania
Conditions: Idiopathic Pulmonary Fibrosis
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
Recruiting
This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
04/16/2024
Locations: Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania +1 locations
Conditions: Idiopathic Pulmonary Fibrosis